《異動股》威高股份(01066.HK)急漲11%價量齊創近期新高
威高股份(01066.HK)繼昨天整固後,今天股價突破近期高位,最高見20.65元,創逾十個月高,現造19.76元,急漲11%,成交急增至4,030萬股,爲七個月來最多,涉資7.89億元。
內地關節集採方案出爐。國家組織高值醫用耗材聯合採購辦公室發佈《國家組織人工關節集中帶量採購公告(第1號)》,由天津市醫藥採購中心實施人工關節集中帶量採購。採購品種爲採購產品爲初次置換人工全髖關節、初次置換人工全膝關節,週期爲2年。
此外,威高上週五公佈,建議分拆山東威高骨科於科創板獨立上市的發售價定爲每股36.22元人民幣,預計集資總額15億人民幣,將用於與威高骨科主營業務相關的項目及發行費用。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.